Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1468435
This article is part of the Research Topic Translation of health technology reassessment and its outputs of disinvestment, de-implementation and de-adoption of drugs and medical devices in practice-what have we learned? View all 4 articles

Kidney Outcomes Associated with SGLT2 Inhibitors Compared to Other Glucose-Lowering drugs: A Real-world Study from China

Provisionally accepted
Xiang Xiao Xiang Xiao Fang Liu Fang Liu *Ji Shuming Ji Shuming Tao Zheng Tao Zheng Tianzhu Wang Tianzhu Wang Dapeng Jiang Dapeng Jiang
  • Department of Nephrology, West China Hospital, Sichuan University, Chengdu, China

The final, formatted version of the article will be published soon.

    This study aimed to investigate the association between the utilization of Sodiumdependent glucose cotransporters inhibitors (SGLT2i) in real-world settings and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in mainland China.In a retrospective analysis of electronic medical records from West China Hospital of Sichuan University, patients with T2D and CKD were included. Patients were divided into two groups, those initiating treatment with SGLT2i and those receiving other glucose-lowering drugs (oGLDs). The primary focus lies in examining the impact of SGLT2i on the decline slope of eGFR and major kidney events in these patients.We enrolled 944 patients diagnosed with both T2D and CKD. Out of these, 605 patients were prescribed SGLT2i, while the remaining 339 patients received oGLDs.The median follow-up duration were 16.8 months and 20.6 months, respectively.Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 ml/min/1.73m 2 per year reduction compared to oGLDs, 95% CI: 4.73-5.15). A total of 101 kidney composite endpoint events occurred, with 31 events in the SGLT2i group and 70 events in the oGLDs group.The use of SGLT2i was associated with a 65% decrease in the risk of kidney composite endpoint events (hazard ratio 0.35, 95% CI 0.19-0.63).In clinical practice, SGLT2i have shown favorable effects on kidney prognosis in patients with T2D and CKD in mainland China. These effects remain consistent across patients with varying risks of CKD progression.

    Keywords: Type 2 Diabetes, Diabetic Kidney Disease, Sodium-dependent Glucose Cotransporters Inhibitors, Real World Study, Kidney Outcomes SGLT2i, Sodium-dependent glucose cotransporters inhibitors, T2D, Type 2 Diabetes, CKD, Chronic Fidney Disease, oGLDs, other Glucose-Lowering Drugs, ESRD, end-stage renal disease, RWS, Real World Studies, RCTs, randomized controlled trials, ACR, Albumin-to-Creatinine Ratio

    Received: 22 Jul 2024; Accepted: 19 Nov 2024.

    Copyright: © 2024 Xiao, Liu, Shuming, Zheng, Wang and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Fang Liu, Department of Nephrology, West China Hospital, Sichuan University, Chengdu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.